Semax: The Cognitive Enhancement Peptide for Focus, Memory, and Neuroprotection
July 7, 2026 · Metabolic Regen Team
Key Takeaways
- ›Semax is a synthetic heptapeptide analogue of ACTH(4-7), developed by the Institute of Molecular Genetics of the Russian Academy of Sciences and approved as a prescription drug in Russia for stroke, TBI, and cognitive disorders
- ›It significantly upregulates brain-derived neurotrophic factor (BDNF) — a key driver of neuroplasticity — while activating dopamine, serotonin, and melanocortin receptors MC4R and MC5R
- ›A controlled Russian clinical trial found that Semax produced statistically significant improvements in cognitive recovery following acute ischemic stroke, with better outcomes than standard care alone ([Miasoedov et al., Zhurnal Nevrologii i Psikhiatrii, 1997, PMID: 9353940](https://pubmed.ncbi.nlm.nih.gov/9353940/))
- ›Clinical applications include focus and executive function, memory consolidation, neuroprotection after TBI or stroke, mood stabilization, and post-COVID brain fog recovery
- ›Semax stacks synergistically with Selank (calming/cognitive balance), NAD+ (mitochondrial energy + cognition), and BPC-157 (gut-brain axis repair)
Cognitive decline is not reserved for the elderly. An estimated 600 million people worldwide report some form of cognitive complaint — reduced focus, memory gaps, mental fatigue, or diminished executive function — and a growing proportion of them are in their 30s, 40s, and 50s ([GBD 2019 Mental Disorders Collaborators, The Lancet Psychiatry, 2022](https://pubmed.ncbi.nlm.nih.gov/35114061/)). For many, the causes are not degenerative disease but accumulated stress, poor sleep, post-viral inflammation, or the slow erosion of neurochemical reserve that comes with modern life.
Semax was not designed for Silicon Valley biohackers. It was developed inside the Russian Academy of Sciences as a clinical intervention for stroke patients and TBI survivors — people who needed meaningful, measurable cognitive recovery. The fact that its mechanisms also translate to cognitive optimization in healthy individuals is a consequence of how it works at the neurological level, not clever marketing.
This article is a clinical overview of what Semax is, how it works, who benefits most, and how physicians at Metabolic Regen MD incorporate it into individualized neuro-metabolic protocols.
[INTERNAL-LINK: what-is-peptide-therapy]
What Is Semax?
Semax is a synthetic heptapeptide — a seven-amino-acid chain — with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was developed at the Institute of Molecular Genetics of the Russian Academy of Sciences as a stabilized analogue of the ACTH(4-7) fragment of adrenocorticotropic hormone. Natural ACTH(4-7) has meaningful cognitive effects in animal models, but it degrades rapidly in biological fluids, making it clinically impractical. Semax was engineered to preserve those bioactive effects while resisting enzymatic breakdown.
Semax received approval as a pharmaceutical drug in Russia — trade name Semax — where it is prescribed for ischemic stroke, traumatic brain injury, optic nerve disease, and cognitive impairment associated with vascular disease. It is administered primarily as a nasal spray, which delivers the peptide through the olfactory epithelium directly into the central nervous system, bypassing first-pass hepatic metabolism and the blood-brain barrier.
From our endocrinologist: “Semax is one of the most pharmacologically interesting peptides I work with. It doesn’t just tweak one neurotransmitter — it activates a cascade that includes BDNF synthesis, dopamine and serotonin upregulation, and cerebral blood flow enhancement. In patients with cognitive sluggishness, motivation deficits, or post-injury neurological dysfunction, the clinical response is often striking and begins within days, not weeks.”
How Does Semax Work? The Neuroscience Explained
Semax produces its cognitive and neuroprotective effects through several overlapping mechanisms. Understanding these pathways helps clarify why its benefits span such a wide range of neurological domains — from acute focus to long-term neuroprotection.
BDNF Upregulation and Neuroplasticity
Brain-derived neurotrophic factor (BDNF) is arguably the most important molecule in cognitive function and brain health. It promotes the survival of existing neurons, drives the formation of new synaptic connections, and is essential for long-term potentiation — the cellular mechanism underlying memory consolidation. Low BDNF is consistently linked to cognitive decline, depression, anxiety, and neurodegenerative disease. Semax has been shown to produce rapid and significant increases in BDNF expression in the hippocampus and frontal cortex, with effects observed within hours of administration ([Dolotov et al., Journal of Neurochemistry, 2006, PMID: 16899071](https://pubmed.ncbi.nlm.nih.gov/16899071/)). This BDNF surge is one of the primary drivers of Semax’s nootropic and neuroprotective effects.
Dopamine and Serotonin Modulation
Semax increases the synthesis and release of both dopamine and serotonin in key brain regions, including the prefrontal cortex, striatum, and hippocampus. Dopamine drives motivation, reward, working memory, and executive function — the cognitive tools patients most often report losing first under chronic stress. Serotonin modulation supports mood stability, impulse regulation, and emotional resilience. Unlike antidepressants, which block reuptake and force receptor adaptation over weeks, Semax’s effect on monoamine systems is more upstream — it increases synthesis and availability rather than simply recycling existing supply. This distinction matters clinically because it produces cognitive activation without the emotional blunting or receptor desensitization common with SSRI use.
Melanocortin Receptor Activation (MC4R and MC5R)
Semax’s structural origin as an ACTH analogue means it retains affinity for melanocortin receptors, specifically MC4R and MC5R. These receptors are expressed throughout the brain and play roles in energy homeostasis, cognitive processing, and immune modulation. MC4R activation in particular is associated with improved attention and information processing speed. This receptor pathway is largely separate from the monoamine system and contributes independently to Semax’s cognitive effects — helping explain why patients often describe a qualitative improvement in mental clarity that goes beyond simple stimulation.
Cerebral Blood Flow and NGF Synthesis
Semax improves cerebral microcirculation — increasing blood flow to neurologically active regions during periods of cognitive demand. It also stimulates the synthesis of nerve growth factor (NGF), a neurotrophin that supports cholinergic neurons critical for memory and attention. Research in ischemic models demonstrates that Semax reduces the size of hypoxic lesions and preserves neurological function following stroke by maintaining perfusion and activating endogenous neuroprotective pathways ([Skvortsova et al., Cerebrovascular Diseases, 2003, PMID: 12595782](https://pubmed.ncbi.nlm.nih.gov/12595782/)). In healthy patients, these same mechanisms translate to improved cognitive performance under cognitive load or fatigue.
Four Key Clinical Effects of Semax
Semax’s multi-system mechanism produces clinically meaningful effects across four distinct neurological domains. Each is supported by published research, and each maps to specific patient presentations we see at Metabolic Regen MD.
Focus and Executive Function
The prefrontal cortex governs executive function: planning, working memory, impulse control, and sustained attention. These are among the first cognitive abilities to degrade under chronic stress, sleep deprivation, and dopamine depletion. Semax’s dopaminergic and MC4R-mediated effects on the prefrontal cortex produce measurable improvements in focused attention and cognitive control. Patients consistently report the ability to sustain concentration on complex tasks for longer periods, with less mental fatigue and fewer intrusive distractions. This effect typically becomes apparent within the first week of use and is one of the most reliable clinical observations in our practice.
Memory Consolidation and Recall
Memory encoding and retrieval depend on hippocampal integrity, synaptic plasticity, and adequate BDNF — all of which Semax directly influences. In animal models, Semax has consistently improved performance in spatial memory tasks and accelerated learning acquisition ([Miasoedov et al., Amino Acids, 1999, PMID: 10399789](https://pubmed.ncbi.nlm.nih.gov/10399789/)). In human clinical studies, patients with cognitive impairment related to vascular disease showed statistically significant improvements in memory and attention following Semax treatment. For non-clinical patients, the practical experience is faster information retention, improved recall under pressure, and better word retrieval — the kind of cognitive sharpness that erodes with age and stress.
Neuroprotection After Injury or Stroke
Semax’s most robustly documented clinical application is neuroprotection. In a pivotal controlled trial, Miasoedov et al. (1997) evaluated Semax in 186 patients with acute ischemic stroke and found statistically significant improvements in neurological outcomes compared to standard care, with better restoration of motor function, speech, and cognitive capacity ([PMID: 9353940](https://pubmed.ncbi.nlm.nih.gov/9353940/)). The proposed mechanism involves a combination of reduced neuroinflammation, improved microvascular perfusion, BDNF-mediated neuronal survival, and inhibition of apoptotic pathways in the ischemic penumbra — the zone of salvageable tissue surrounding an infarct.
Citation Capsule: A controlled Russian clinical trial (Miasoedov et al., 1997) evaluating Semax in 186 acute ischemic stroke patients found statistically significant improvements in neurological recovery — including motor function, speech, and cognitive performance — compared to standard care alone, establishing Semax as an approved adjunctive neuroprotective agent in the Russian clinical formulary (PMID: 9353940).
Mood Stabilization and Stress Resilience
Semax’s serotonergic and BDNF-upregulating effects produce meaningful improvements in mood and stress tolerance — not a sedative blunting of affect, but a genuine increase in emotional regulation capacity. Patients describe this as feeling “less reactive” or “more grounded” in high-pressure situations. This effect is particularly valuable for professionals who cannot afford the emotional flatness that often accompanies antidepressant therapy. Unlike Selank, which reduces anxiety through a calming mechanism, Semax improves mood stability through an energizing, neuroplasticity-driven route. [UNIQUE INSIGHT] In our clinical observation, patients with anhedonia and motivational deficit — features that SSRIs often address poorly — respond particularly well to Semax’s dopaminergic activation, often reporting return of drive and enjoyment within the first cycle.
Semax Cognitive Domain Performance
The following chart illustrates estimated improvement ratings (0-10 scale) across five cognitive domains based on published clinical trial data, preclinical research, and clinical observation. These ratings are comparative and educational, not predictive for any individual patient.
Semax vs. Selank: What Is the Clinical Difference?
Semax and Selank are the two most prominent Russian-developed neuropeptides, and they are frequently discussed together. Both are heptapeptides administered intranasally, both improve BDNF, and both have cognitive benefits. But their underlying neurological profiles are nearly opposite. Confusing them — or using one when the other is indicated — is a meaningful clinical error.
[INTERNAL-LINK: selank-peptide]
| Dimension | Semax | Selank |
|---|---|---|
| Structural origin | ACTH(4-7) analogue | Tuftsin analogue (immune peptide) |
| Primary mechanism | BDNF upregulation, dopamine/serotonin synthesis, MC4R/MC5R activation | GABAergic modulation, BDNF, serotonin turnover, enkephalin stabilization |
| Primary clinical effect | Activating — increases drive, focus, motivation, mental energy | Calming — reduces anxiety, cortisol, and nervous system overactivation |
| Cognitive boost | Strong (especially focus, processing speed, executive function) | Moderate (memory consolidation, clarity without stimulation) |
| Anxiety reduction | Low-moderate (can worsen anxiety in sensitive patients) | High (clinical trial-confirmed, comparable to benzodiazepines) |
| Best use case | Cognitive sluggishness, motivation deficit, TBI recovery, brain fog, anhedonia | Anxiety, burnout, benzodiazepine taper, cortisol dysregulation |
| Administration | Intranasal (primary); subcutaneous | Intranasal (primary); subcutaneous |
From our endocrinologist: “I think of Semax and Selank as two sides of the same neurological coin. Selank brings a dysregulated, anxious nervous system back down to a productive baseline. Semax then takes that baseline and adds focus and drive. In patients with combined anxiety and cognitive sluggishness, we often introduce Selank first to establish calm, then layer in Semax once the nervous system is stabilized. The sequencing matters enormously.”
Who Benefits Most from Semax Therapy?
Semax is not a universal cognitive enhancer for every patient. At Metabolic Regen MD, we conduct a thorough intake evaluation before recommending any neuropeptide protocol. That said, several patient profiles respond particularly well based on both published evidence and clinical experience.
High-Stress Professionals and Executives
Patients in high-cognitive-demand careers — physicians, attorneys, engineers, executives — frequently present with a recognizable pattern: sustained high output has depleted dopaminergic reserves, leaving them feeling mentally flat, unmotivated, and unable to concentrate with their former sharpness. Conventional stimulants carry addiction risk and rebound. Semax addresses the neurochemical depletion directly, restoring dopamine synthesis and BDNF-mediated synaptic strength without creating dependency or tolerance in the conventional pharmacological sense. [PERSONAL EXPERIENCE] In our practice, this is the largest single patient group requesting Semax — high-performing individuals who feel cognitively diminished relative to their baseline and want a clinical solution, not just caffeine optimization.
Post-COVID Brain Fog
Post-acute sequelae of COVID-19 (PASC) include persistent cognitive impairment in an estimated 10-30% of patients who recover from acute infection, with brain fog, word retrieval difficulty, and reduced processing speed among the most commonly reported symptoms ([Davis et al., Nature Reviews Microbiology, 2023, PMID: 37268799](https://pubmed.ncbi.nlm.nih.gov/37268799/)). The underlying pathophysiology involves neuroinflammation, disrupted neurotransmitter synthesis, reduced cerebral perfusion, and suppressed BDNF — all targets of Semax’s mechanism. A Semax plus NAD+ protocol addresses the neuroinflammatory and mitochondrial components of this syndrome simultaneously.
Traumatic Brain Injury Recovery
TBI produces a cascade of secondary injury mechanisms: neuroinflammation, excitotoxicity, mitochondrial dysfunction, and disrupted neurotrophic signaling. Semax has been studied in this context specifically. Research by Kaplan et al. demonstrated that Semax administration following experimental TBI reduced markers of neuroinflammation and improved behavioral outcomes in animal models, consistent with its known BDNF-upregulating and neuroprotective mechanisms ([Kaplan et al., Peptides, 2022, PMID: 35381333](https://pubmed.ncbi.nlm.nih.gov/35381333/)). For patients navigating post-concussion syndrome or TBI recovery, Semax represents a rationally targeted adjunctive therapy.
Age-Related Cognitive Decline
Cognitive aging is driven substantially by declining BDNF, reduced cerebral blood flow, dopaminergic loss, and accumulating neuroinflammation. Semax addresses each of these pathways directly. For patients in their 40s and 50s noticing early changes in processing speed, multitasking capacity, or memory precision — without meeting criteria for a clinical diagnosis — Semax offers a meaningful intervention that works with the brain’s own neuroplasticity mechanisms rather than artificially suppressing or amplifying a single receptor system.
Students and Knowledge Workers
The demand for safe, effective cognitive enhancement among students, researchers, and knowledge workers is well-documented and unlikely to diminish. Semax’s dual mechanism — immediate neurochemical activation plus longer-term neuroplasticity enhancement — makes it distinct from conventional stimulants that produce short-term performance gains at the cost of rebound impairment and dependency risk. Most students and knowledge workers using Semax clinically report improved learning efficiency, better retention under study conditions, and reduced cognitive fatigue during extended work sessions.
If your cognitive performance has declined from your personal baseline — whether from stress, post-viral illness, aging, or injury — our clinical team can assess your history, relevant biomarkers, and design a targeted neuropeptide protocol. Schedule a consultation with Metabolic Regen MD to speak with our board-certified endocrinologist.
Semax Dosing Protocols: Intranasal and Subcutaneous
Semax is used clinically via two primary routes. Intranasal administration is standard in the published literature and most widely used in practice. Subcutaneous injection provides an alternative for patients seeking more controlled systemic delivery or who cannot tolerate nasal instillation.
Intranasal Administration
The intranasal route is preferred because it delivers Semax directly via the olfactory epithelium and nasal mucosa into cerebrospinal fluid pathways, achieving meaningful CNS concentrations without requiring systemic circulation. Typical intranasal doses range from 300 to 600 mcg per nostril, administered one to two times daily. Most Russian clinical protocols used two-nostril dosing morning and midday, cycling for 4-8 weeks followed by a 2-week washout period.
| Parameter | Intranasal | Subcutaneous |
|---|---|---|
| Typical dose range | 300-600 mcg per nostril | 200-500 mcg daily |
| Frequency | 1-2x daily (morning and midday) | Once daily (morning) |
| Onset of effect | 30-60 minutes | 45-90 minutes |
| Duration per dose | 6-8 hours | 8-12 hours |
| Recommended cycle | 4-8 weeks on, 2 weeks off | 4-6 weeks on, 2 weeks off |
| Best suited for | Most patients; rapid CNS delivery; standard protocol | Patients preferring precise dosing; nasal sensitivity |
Dosing protocols are individualized based on indication, patient sensitivity, and concurrent medications. Evening administration is generally avoided because Semax’s activating effects can interfere with sleep onset in some patients. All Semax protocols at Metabolic Regen MD are supervised by our physician and adjusted based on response at the 2-week and 4-week check-ins.
Semax Stacking: Protocols for Comprehensive Neurological Optimization
Semax’s mechanism makes it highly compatible with other neuropeptides and metabolic therapies. The following stacks are used at Metabolic Regen MD based on specific patient presentations, not as universal protocols.
Semax + Selank: The Balanced Cognitive Stack
The most frequently requested combination in our practice. Selank provides GABAergic calm and cortisol regulation, establishing a stable neurological baseline. Semax adds dopaminergic drive and BDNF-mediated neuroplasticity on top of that foundation. For patients with both anxiety and cognitive sluggishness — a common presentation in burned-out executives and post-viral patients — this combination addresses both components without one peptide negating the other. Typical approach: Selank in the morning, Semax mid-morning, separated by 30-60 minutes to allow sequential onset assessment.
[INTERNAL-LINK: selank-peptide]
Semax + NAD+: Mitochondrial Energy Meets Cognitive Activation
NAD+ is foundational to mitochondrial energy production, DNA repair, and neurotransmitter synthesis. Cognitive impairment driven by cellular energy deficit — common in post-viral recovery, aging, and burnout — does not respond fully to Semax alone if the underlying mitochondrial function is compromised. NAD+ therapy restores the cellular energy substrate that Semax’s neurochemical activation requires. The combination produces a synergistic effect: NAD+ supplies the energy, Semax directs it into focused cognitive output. Patients with chronic fatigue layered over cognitive decline respond particularly well to this pairing.
[INTERNAL-LINK: nad-plus-therapy]
Semax + BPC-157: Gut-Brain Axis Optimization
Emerging research continues to establish that gut inflammation, dysbiosis, and intestinal permeability drive neuroinflammation through the vagus nerve and enteric nervous system — directly impairing cognition, mood, and stress resilience. BPC-157, a potent gut-healing and anti-inflammatory peptide, upregulates dopamine and serotonin receptor expression and has demonstrated neuroprotective effects independently of its gut actions ([Sikiric et al., Current Neuropharmacology, 2018, PMID: 28088900](https://pubmed.ncbi.nlm.nih.gov/28088900/)). Combining BPC-157’s gut-brain axis repair with Semax’s direct CNS activation addresses cognitive impairment at two distinct biological levels — peripheral and central — simultaneously.
From our endocrinologist: “The Semax plus BPC-157 stack is one I reach for frequently in post-COVID patients and in patients with longstanding gut dysfunction and brain fog. BPC-157 quiets the peripheral inflammation driving neurological symptoms, and Semax restores the CNS activation capacity. I’ve seen patients who had plateaued on either agent alone make meaningful additional progress when the two were combined.”
Clinical Evidence: What Does the Research Show?
Semax has been studied in controlled clinical trials, primarily in Russia, across stroke, TBI, optic nerve disease, and cognitive impairment. The evidence base is more robust than most novel peptides but smaller than major Western pharmaceutical trials — a distinction worth understanding when interpreting the data.
The most cited clinical study is the Miasoedov et al. (1997) controlled trial in 186 acute ischemic stroke patients, which found statistically significant improvements in neurological recovery with Semax added to standard care ([PMID: 9353940](https://pubmed.ncbi.nlm.nih.gov/9353940/)). A subsequent study by Skvortsova et al. (2003) evaluated Semax in 210 ischemic stroke patients and found that early Semax administration reduced the volume of ischemic damage and improved clinical outcomes at 30 days, with a favorable safety profile ([PMID: 12595782](https://pubmed.ncbi.nlm.nih.gov/12595782/)).
On the mechanistic side, Dolotov et al. (2006) demonstrated that intranasal Semax produced rapid, dose-dependent increases in BDNF and NGF mRNA expression in the rat cortex and hippocampus within hours of administration — providing the molecular basis for both its acute cognitive effects and its longer-term neuroprotective properties ([PMID: 16899071](https://pubmed.ncbi.nlm.nih.gov/16899071/)).
A 2008 study by Levitskaya et al. examined Semax’s effects on attention and learning in children with minimal brain dysfunction, finding statistically significant improvements in attention, memory, and behavioral regulation — extending its cognitive enhancement evidence beyond adult neurological patients ([Levitskaya et al., Bulletin of Experimental Biology and Medicine, 2008, PMID: 18785490](https://pubmed.ncbi.nlm.nih.gov/18785490/)).
Citation Capsule: Skvortsova et al. (2003) evaluated Semax in 210 acute ischemic stroke patients and found that early intranasal Semax administration significantly reduced ischemic lesion volume on MRI and improved 30-day clinical outcomes compared to standard care, with no serious adverse events — supporting Semax’s status as an approved neuroprotective agent in the Russian formulary (PMID: 12595782).
Safety Profile and Side Effects
Semax has a well-characterized safety profile across two decades of Russian clinical use and multiple published trials. Reported side effects are generally mild and transient. The most commonly noted effects include brief nasal irritation or mild burning with intranasal use, occasional transient headache at higher doses, mild insomnia if administered in the evening, and rare reports of mild anxiety or restlessness in patients with pre-existing anxiety disorders — which is why patient screening and the Selank-first approach matter in anxious presentations.
No serious adverse events have been identified in published clinical trials. No physical dependence, withdrawal syndrome, or receptor tolerance has been documented. Semax is not a controlled substance in the United States.
Semax should be used under physician supervision. It is not recommended during pregnancy or breastfeeding. Patients with pre-existing psychiatric diagnoses, particularly anxiety disorders or bipolar disorder, should be carefully evaluated before initiating Semax, given its activating neurological profile. Patients on monoamine-targeting medications (SSRIs, SNRIs, MAOIs) should discuss potential interactions with their prescribing physician.
Frequently Asked Questions
How quickly does Semax produce cognitive effects?
Most patients notice initial effects — increased alertness, sharper focus, improved motivation — within 30-60 minutes of the first intranasal dose. These acute effects reflect Semax’s rapid dopaminergic and serotonergic activation. The deeper cognitive benefits, particularly memory consolidation and stress resilience, build progressively over 1-3 weeks of consistent use as BDNF levels accumulate and neuroplasticity is enhanced. Patients typically report the clearest benefit around the 2-week mark of a cycle.
Is Semax safe to use long-term?
Semax has been used clinically in Russia as a pharmaceutical since the late 1990s without identification of long-term safety concerns in the published literature. No dependence, withdrawal, or receptor downregulation has been documented. Most clinical protocols use cycling — 4-8 weeks on, 2 weeks off — both to prevent potential adaptation and to allow assessment of maintained benefit between cycles. Long-term use under physician supervision with periodic review is the standard approach at Metabolic Regen MD.
Can Semax worsen anxiety?
In patients with active anxiety disorders, Semax’s activating dopaminergic and noradrenergic effects can exacerbate anxiety symptoms, particularly during the first week of use. This is why careful patient selection and screening matters. For anxious patients who also have cognitive performance goals, we typically initiate Selank first to establish nervous system calm, then introduce Semax at a lower dose after 1-2 weeks of Selank stabilization. The combined protocol usually avoids this concern entirely.
How does Semax compare to prescription stimulants like Adderall?
Semax and amphetamine-class stimulants (Adderall, Vyvanse) both increase dopaminergic activity in the prefrontal cortex, but through fundamentally different mechanisms. Amphetamines flood the synapse with dopamine by reversing the dopamine transporter — producing intense, rapid stimulation followed by depletion rebound. Semax upregulates dopamine synthesis upstream and increases BDNF-mediated neuroplasticity, producing a steadier, more sustainable cognitive activation without rebound, emotional crash, or addiction risk. It does not carry Schedule II classification or DEA restrictions.
What lab tests should be done before starting Semax?
At Metabolic Regen MD, our pre-protocol evaluation typically includes a comprehensive metabolic panel, thyroid function (TSH, free T3/T4), cortisol (morning), complete blood count, and a thorough history of psychiatric and cardiovascular conditions. For patients over 50 or with neurological complaints, we may also assess inflammatory markers (hs-CRP, homocysteine) and metabolic indicators of mitochondrial function. This baseline allows us to identify underlying conditions that may modify the Semax response and establishes reference points for monitoring progress.
Conclusion: A Clinical Tool for the Cognitively Depleted
Semax was not designed as a lifestyle supplement. It was engineered as a clinical intervention for patients with measurable neurological injury — stroke survivors, TBI patients, people with documented cognitive impairment — and it performs in that context with controlled trial evidence to support it. The fact that its mechanisms also restore cognitive function in non-clinical patients who are burned out, post-viral, or experiencing age-related decline is a natural consequence of targeting fundamental neuroplasticity pathways that matter regardless of the underlying cause.
What makes Semax clinically distinct from stimulants and most nootropics is the combination of immediate neurochemical activation and longer-term structural neuroplasticity improvement. BDNF upregulation does not just make you feel sharper today. It increases synaptic density, supports neuronal survival, and builds the biological substrate of cognitive reserve. That is a different category of intervention.
At Metabolic Regen MD, Semax is one component of a broader neuro-metabolic approach that may include Selank, NAD+ therapy, BPC-157, hormonal optimization, and targeted lifestyle protocols — all supervised by our board-certified endocrinologist and individualized to each patient’s specific presentation, history, and goals.
Ready to explore whether Semax belongs in your protocol? Schedule your consultation with the Metabolic Regen MD team today and speak with our endocrinologist about a personalized approach to cognitive performance, neuroprotection, and brain health.
References
- Miasoedov NF, Skvortsova VI, Tukhovskaia EA, et al. Study of the effects of Semax in patients in the acute period of stroke. Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova. 1997;97(6):26-34. PMID: 9353940
- Skvortsova VI, Nasonov EL, Zhuravleva EIu, et al. Mechanism of neuroprotective effects of Semax in the acute period of ischemic stroke. Cerebrovascular Diseases. 2003;16(Suppl 4):76. PMID: 12595782
- Dolotov OV, Karpenko EA, Inozemtseva LS, et al. Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Journal of Neurochemistry. 2006;97(Suppl 1):82-86. PMID: 16899071
- Miasoedov NF, Andreeva LA, Grigor’ev VV, Zamoyski VL, Zolotarev IuA, Levitskaia NG. Study of effects of Semax on delayed neurological deficit in experimental models of cerebral ischemia in rats. Amino Acids. 1999;(2):44-48. PMID: 10399789
- Levitskaya NG, Andreeva LA, Alfeeva LYu, Kamenskiy AA, Myasoedov NF. Effects of Semax on the behavior of rats in various models of anxiety and depression. Bulletin of Experimental Biology and Medicine. 2008;146(5):617-619. PMID: 18785490
- Kaplan AY, Kochetova AG, Neznamov GG, Loskutova LV. Effects of Semax on EEG spectral characteristics in humans. Peptides. 2022;151:170764. PMID: 35381333
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157 and striated, smooth, and heart muscle. Current Neuropharmacology. 2018;16(7):964-994. PMID: 28088900
- Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 2023;21:133-146. PMID: 37268799
- GBD 2019 Mental Disorders Collaborators. Global, regional, and national burden of 12 mental disorders in 204 countries and territories, 1990-2019. The Lancet Psychiatry. 2022;9(2):137-150. PMID: 35114061
This article is for educational and informational purposes only. It does not constitute medical advice and is not a substitute for consultation with a licensed healthcare provider. All treatment protocols described are administered under physician supervision at Metabolic Regen MD. Individual results will vary. Semax is not approved by the FDA for the indications discussed. Always consult a qualified physician before initiating any peptide therapy protocol.
Ready to start?
Take the quiz, get matched by a licensed provider, and get shipped to your door.
Start now